» Articles » PMID: 33343780

Microfluidic-based Approaches for COVID-19 Diagnosis

Overview
Date 2020 Dec 21
PMID 33343780
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Novel coronavirus, COVID-19, erupted in Wuhan, China, in 2019 and has now spread to almost all countries in the world. Until the end of November 2020, there were over 50 × 10 people diagnosed with COVID-19 worldwide and it caused at least 1 × 10 deaths. These numbers are still increasing. To control the spread of the pandemic and to choose a suitable treatment plan, a fast, accurate, effective, and ready-to-use diagnostic method has become an important prerequisite. In this Review, we introduce the principles of multiple off-site and on-site detection methods for virus diagnosis, including qPCR-based, ELISA-based, CRISPR-based methods, etc. All of these methods have been successfully implanted on the microfluidic platform for rapid screening. We also summarize currently available diagnostic methods for the detection of SARS, MERS, and COVID-19. Some of them not only can be used to analyze the SARS and MERS but also have the potential for COVID-19 detection after modifications. Finally, we hope that understanding of current microfluidic-based detection approaches can help physicians and researchers to develop advanced, rapid, and appropriate clinical detection techniques that reduce the financial expenditure of the society, accelerate the examination process, increase the accuracy of diagnosis, and eventually suppress the worldwide pandemic.

Citing Articles

Microfluidic detection of viruses for human health.

Yoon J, Chen C Biomicrofluidics. 2022; 16(6):060401.

PMID: 36337833 PMC: 9633095. DOI: 10.1063/5.0130555.


Translating diagnostics and drug delivery technologies to low-resource settings.

Euliano E, Sklavounos A, Wheeler A, McHugh K Sci Transl Med. 2022; 14(666):eabm1732.

PMID: 36223447 PMC: 9716722. DOI: 10.1126/scitranslmed.abm1732.


Microfluidics-based strategies for molecular diagnostics of infectious diseases.

Wang X, Hong X, Li Y, Li Y, Wang J, Chen P Mil Med Res. 2022; 9(1):11.

PMID: 35300739 PMC: 8930194. DOI: 10.1186/s40779-022-00374-3.


Powerful CRISPR-Based Biosensing Techniques and Their Integration With Microfluidic Platforms.

Chen B, Li Y, Xu F, Yang X Front Bioeng Biotechnol. 2022; 10:851712.

PMID: 35284406 PMC: 8905290. DOI: 10.3389/fbioe.2022.851712.


Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic.

Dhar B Anal Bioanal Chem. 2022; 414(9):2903-2934.

PMID: 35211785 PMC: 8872642. DOI: 10.1007/s00216-022-03918-7.

References
1.
Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X . Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020; 6:11. PMC: 7040011. DOI: 10.1038/s41421-020-0147-1. View

2.
Paweska J, Burt F, Swanepoel R . Validation of IgG-sandwich and IgM-capture ELISA for the detection of antibody to Rift Valley fever virus in humans. J Virol Methods. 2005; 124(1-2):173-81. DOI: 10.1016/j.jviromet.2004.11.020. View

3.
Heller M . DNA microarray technology: devices, systems, and applications. Annu Rev Biomed Eng. 2002; 4:129-53. DOI: 10.1146/annurev.bioeng.4.020702.153438. View

4.
Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

5.
Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N . Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000; 28(12):E63. PMC: 102748. DOI: 10.1093/nar/28.12.e63. View